Sirs,
The frequency and severity of urge incontinence and overactive bladder in a population increase with advancing age [1, 2] . The initial treatment for patients seeking medical care for these symptoms is often bladder training. Subsequent treatment with anticholinergic agents may be initiated in the absence of a sufficient treatment effect by bladder training alone.
There is evidence that treatment with anticholinergics for urge incontinence provides beneficial effects on diseasespecific quality of life [3] . However, these effects are small in many cases, and mild adverse effects are common. Only a proportion of patients are therefore satisfied with the effect of the treatment [4, 5] .
The anticholinergic drugs provided in Sweden are oxybutynin (tablets, patches), tolterodine, solifenacin, darifenacin and fesoterodine. All products except oxybutynin (tablets) are originator products without generic competition and are more costly than the generic oxybutynin. During the last 10 years tolterodine has been by far the most widely used alternative in Sweden. Systematic literature reviews have concluded that treatment with oxybutynin (tablets) results in an equivalent medical effect to tolterodine but that it also gives rise to a somewhat higher frequency of common side effects, such as dry mucous membranes [6] .
In a recently published study in the European Journal of Clinical Pharmacology, Broström and Hallas [7] described the outcome of an analysis based on individual-level prescription data from a county in Denmark. The persistence of anticholinergic drug use was calculated based on dispensed products, and Kaplan-Meyer curves were generated for individual substances. The proportion of individuals who remained on continuous treatment was approximately 50% 3 months after initiation of treatment and approximately 30% after 6 months. About 20% of patients remained on continuous treatment for longer than 1 year. Adherence was lower for oxybutynin and higher for trospium.
Here, we briefly report the results of a similar analysis based on the Swedish prescribed drug register. The register has been described previously [8] . The analysis was carried out in conjunction with a health economic analysis performed by the Dental and Pharmaceutical Benefits Agency in Sweden. The aims were to study the persistence of anticholinergic drug use and to compare persistence between products when possible. Data have only been handled in aggregated form by the external investigators (i.e. only the author HS had access to the register), and according to Swedish legislation it is not necessary for the National Board of Health and Welfare to have approval from an ethics committee. Data for originator drugs were not analysed separately due to regulations of the register. Predictors of persistence (age, gender) were analysed based on the results of Broström and Hallas [7] Based on the analysis, it appears that the adherence rate to continuous treatment with anticholinergics in Sweden is similar to that in Denmark. Of the 47,685 individuals who received their first prescription of anticholinergics in 2007 and 2008, fewer than 50% filled their second prescription within 120 days (see Table 1 ). The normally dispensed drug quantity in Sweden lasts approximately 90 days. After 1 year the adherence rate was less than 20%.
Switching between types of anticholinergic drugs does not seem to be a major cause of the rather low adherence to treatment with a specific product. Warfarin [Anatomical Therapeutic Chemical Classification (ATC) B01AA03] had a clearly higher retention rate, which partly validates the method. We did not correct our data for death or migration, which is a limitation. Age was positively correlated with persistence (r 0,74) but was, due to a reduced rate in the highest age group, not significant (p = 0.15). Gender did not affect persistence. The time interval between refills (approximately 60 days) is likely to be a reflection of when a refill of a product is reimbursed in Sweden.
The relatively low adherence may be related to the observation that several patients in randomized trials report no or limited satisfaction with active treatment [4, 5] . The adherence to treatment with generic oxybutynin was somewhat lower than for treatment with originator drugs. The documented higher frequency of common adverse effects with oxybutynin (tablets) is likely to be one of the causes of the lower adherence rate. Other reasons may be a more widespread use as temporary symptomatic treatment or a different subgroup of patients or prescribers that use the product. The age distributions of patients on oxybutynin or originator drug were similar. who collected the prescribed product continuously after the first prescription and the median time between first prescription and subsequent refills. Incident users were identified from the years 2007 and 2008. Maximum time allowed between prescriptions was 120 days. Analysis was performed on an individual product level, but presented in aggregated form to external investigators. Oxybutynin [tablet]: n=479. Originator drugs (tolterodine, solifenacin, fesoterodin, darifenacin, oxybutynin [patch]): n=47,101. An analysis on ATC5 level (i.e. G04BD) was included to account for patients switching between treatments. An analysis of another drug class (B01AA03, warfarin) was included to validate the method. An approximation of the accumulated possible treatment time for a fully compliant patient with each filled prescription is included in the rightmost column. (oxybutynin [tablet] is however rarely prescribed as start package)
